ABG Sundal Collier initiates equity research on FluoGuide
Copenhagen, Denmark, 19 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform that the Swedish investment bank ABG Sundal Collier (ABG) has initiated equity research coverage on FluoGuide.
Starting today, ABG has initiated its equity research, meaning that ABG will continuously monitor and analyze FluoGuide’s operations, its products, markets, and competitors. The equity research is proprietary information only to ABG clients.
For further information, please contact:
Morten Albrechtsen, CEO
+45 24 25 62 66
Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is has demonstrated early evidence of efficacy of F001 as well as it to be well tolerated and safe in the ongoing proof-of-concept clinical study (phase I/II) in patients with high grade glioma undergoing surgery. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.